calendar
94 catalysts · 3,827 phase readout · 2,126 8k filing · 277 earnings · 172 phase 2 completion · 133 drug shortage · 109 grant
next 91 dayslessmore
MonWedFri
94 catalysts · 3,827 phase readout · 2,126 8k filing · 277 earnings · 172 phase 2 completion · 133 drug shortage · 109 grant
Sponsor: DR REDDYS LABS SA. Form: FILM. Route: BUCCAL, SUBLINGUAL
Sponsor: DR REDDYS LABS SA. Form: FILM. Route: BUCCAL, SUBLINGUAL
Sponsor: DR REDDYS LABS SA. Form: FILM. Route: BUCCAL, SUBLINGUAL
Sponsor: DR REDDYS LABS SA. Form: FILM. Route: BUCCAL, SUBLINGUAL
Sponsor: DR REDDYS LABS SA. Form: FILM. Route: BUCCAL, SUBLINGUAL
Sponsor: GE HLTHCARE INC. Form: SOLUTION. Route: INTRAVENOUS
Sponsor: GENENTECH INC. Form: TABLET. Route: ORAL
Sponsor: MANKIND PHARMA. Form: SOLUTION/DROPS. Route: OPHTHALMIC
Sponsor: RK PHARMA. Form: TABLET. Route: ORAL
Sponsor: REGENERON PHARMACEUTICALS. Form: INJECTABLE. Route: INJECTION
Sponsor: EXTROVIS. Form: SOLUTION. Route: INTRAVENOUS
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: QUAGEN. Form: SYRUP. Route: ORAL
Sponsor: YICHANG HUMANWELL. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: GLENMARK SPECLT. Form: CREAM. Route: TOPICAL
Sponsor: MARKSANS PHARMA. Form: CAPSULE, DELAYED RELEASE. Route: ORAL
Sponsor: GLENMARK PHARMS LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: GLENMARK PHARMS LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: IMPAX LABS. Form: CAPSULE. Route: ORAL
Sponsor: IMPAX LABS. Form: CAPSULE. Route: ORAL
Sponsor: AUROBINDO PHARMA LTD. Form: TABLET. Route: ORAL
Therapy area: Dermatology. Indication: Vitiligo
Sponsor: ABBVIE. Form: IMPLANT. Route: INTRAVITREAL
Sponsor: ACCORD HLTHCARE. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: AUROBINDO PHARMA. Form: CAPSULE. Route: ORAL
Therapy area: Gastrointestinal. Indication: Anal Fissure, Hemorrhoids
Therapy area: Central Nervous System, Gastrointestinal. Indication: Inguinal Hernia, Post-Operative Pain
Therapy area: Immunology. Indication: Rheumatoid Arthritis
Therapy area: Immunology. Indication: Immunoglobulin G4-Related Disease (IgG4-RD)
Therapy area: Ophthalmology. Indication: Choroidal Neovascularization, Dry (Atrophic) Macular Degeneration, Geographic Atrophy
Therapy area: Immunology. Indication: Rheumatoid Arthritis
Therapy area: Cardiovascular, Dermatology. Indication: Melasma (Chlosma), Venous Thromboembolism
Therapy area: Respiratory. Indication: Obstructive Sleep Apnea
Therapy area: Genito Urinary System, Non Malignant Disorders. Indication: Burning Sensation, Oral Submucosal Fibrosis
Therapy area: Oncology. Indication: Head And Neck Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Hypopharyngeal Cancer, Laryngeal Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Recurrent Head And Neck Squamous Cell Carcinoma
Therapy area: Oncology. Indication: Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Therapy area: Respiratory. Indication: Seasonal Allergic Rhinitis
Therapy area: Ophthalmology. Indication: Open-Angle Glaucoma
Therapy area: Metabolic Disorders. Indication: Fabry Disease
Therapy area: Metabolic Disorders. Indication: Type 2 Diabetes
Sponsor: NOVARTIS. Form: TABLET. Route: ORAL